Evidence map›Paper›PMID 38707655›Full record

ArticleJCEM case reports2024

Correlation Between Glycemic Control and Serum Thyroglobulin Levels in a Patient With RAI-Refractory Thyroid Cancer.

Yuji Hataya, Takumi Nomura, Yuko Fujishima, Kanta Fujimoto, Toshio Iwakura, Naoki Matsuoka

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCEM case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuji HatayaDepartment of Diabetes and Endocrinology, Kobe City Medical Center General Hospital, 2-1-1, Kobe, Hyogo 650-0047, Japan.ORCID https://orcid.org/0000-0002-4710-6393
Takumi NomuraDepartment of Diabetes and Endocrinology, Kobe City Medical Center General Hospital, 2-1-1, Kobe, Hyogo 650-0047, Japan.
Yuko FujishimaDepartment of Diabetes and Endocrinology, Kobe City Medical Center General Hospital, 2-1-1, Kobe, Hyogo 650-0047, Japan.
Kanta FujimotoDepartment of Diabetes and Endocrinology, Kobe City Medical Center General Hospital, 2-1-1, Kobe, Hyogo 650-0047, Japan.
Toshio IwakuraDepartment of Diabetes and Endocrinology, Kobe City Medical Center General Hospital, 2-1-1, Kobe, Hyogo 650-0047, Japan.
Naoki MatsuokaDepartment of Diabetes and Endocrinology, Kobe City Medical Center General Hospital, 2-1-1, Kobe, Hyogo 650-0047, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a risk factor for thyroid cancer development. Serum thyroglobulin (Tg) levels are useful as sensitive and specific tumor markers for monitoring radioiodine (RAI)-refractory thyroid cancer; however, the impact of glycemic control on serum Tg levels is poorly understood. Here, we present a case of a female patient with lung metastases of RAI-refractory thyroid cancer in whom glycemic control may have influenced the serum Tg levels. Despite receiving thyroid-stimulating hormone suppression therapy, her serum Tg levels remained elevated. Subsequently, she developed type 2 diabetes and was administered antidiabetic medications for 6 years. Throughout the course of diabetes management, her serum Tg levels fluctuated according to the level of glycemic control, showing a strong correlation with her hemoglobin A1c levels (

Indexed as

glycemic controlmetforminradioiodine-refractory thyroid cancerthyroglobulintype 2 diabetes

Identifiers

PMID38707655
PMCPMC11066931

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.